Warning: count(): Parameter must be an array or an object that implements Countable in /home/logicben/public_html/drugtrialsformoney.com/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 390

Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC

Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC
Conditions:   Small-cell Lung Cancer;   Relapsed Small Cell Lung Cancer;   Recurrent Small Cell Lung Cancer
Interventions:   Drug: Nivolumab;   Drug: Ipilimumab;   Drug: Lurbinectedin
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   Bristol-Myers Squibb;   PharmaMar
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

October 31, 2020 / by / in
Comments